CLOSE
Power of 3

by -
0 2562
Michelle and Paul Paternoster

By Daniel Dunaief

Part 2

Three families and their foundations jump-started a research mission on Long Island that offers a chance for change. Their stories reflect a desire to remember their family members and a need to offer hope and help to others.

Christina Renna

Christina Renna with sister Rae Marie Renna

Phil Renna waited while his 16-year old daughter Christina spoke with her doctor. He and his wife Rene had decided to allow their daughter, who was battling a form of connective tissue cancer called rhabdomyosarcoma (RMS), to be involved in decisions about her treatment.

When Christina came out of the room, Phil, director of operations in the communications department at Cold Spring Harbor Laboratory, asked if he should also speak with the doctor. Christina said it wasn’t necessary. On the way home, she told him it had to be a “really good Christmas.”

He knew what that meant, although she also asked him not to tell anyone how close she was to the end of her life.

Renna and parents throughout the country have had to cope with the agony of rhabdomyosarcoma, which mostly affects children. People battling this cancer have turned to medicine for help, only to find that the treatment options are limited.

That, Renna and others say, was as unacceptable to them when their children were battling cancer as it is now, when the next generation is struggling with this illness.

RMS doesn’t receive the same level of funding nationally as cancers that affect more people, such as breast, lung and prostate cancer, but the agony and suffering are just as significant.

Amid their battles with the disease, families have turned to their support groups, including friends, extended family, and community members to raise funds for basic research, hoping grass roots efforts allow future generations to have longer, healthier lives.

Supported by these funds and a willingness to fill a research gap, Cold Spring Harbor Laboratory CEO Bruce Stillman has backed efforts to gather information and to support research that may also help people with other forms of cancer.

Renna, who lives in Lindenhurst, struggled with his role as father and protector when Christina developed rhabdomyosarcoma.

“I’m supposed to protect my kids,” Renna said. “I should be able to tell them, ‘It’s going to be okay.’”

Renna went to Stillman to ask whether Christina, who was a patient at Memorial Sloan Kettering, might get better care somewhere else.

After conducting some research, Stillman told his colleague about the lack of basic research and other treatment options.

“That was a crushing moment for me,” Renna said.

During treatment, Christina had to be at Memorial Sloan Kettering at 7 a.m., which meant he and Christina’s mother Rene got in the car at 5 a.m. with their daughter.

Renna dropped them off, drove back to work, where he’d put in a full day, drive back to the hospital and return home at 10:30 p.m.

“That was every night, five days a week,” Renna recalled. While those were tough days, Renna said he and his wife did what they needed to do for their daughter.

Five years after his daughter died at the age of 16, Renna drove home from work one day to find his shirt was wet. It took him a while to realize the moisture came from the tears, as he cried his way back to his house. At one point, he thought he had post-traumatic stress disorder.

Renna continues to raise money to support research into this disease, while also helping people create and develop their own foundations, often after enduring similar pain.

“Every single foundation that has come and given money to the lab, I have personally met with,” he said. “I helped our advancement team onboard them.”

As someone who has lost a child and understands what a parent can be feeling, Renna is committed to helping others cope with their grief. 

“For me, it is about helping the lab, but also about helping families honor the memory of their child in a meaningful way and what better way than to help another family and perhaps find a cure,” he wrote in an email.

Renna believes investments in research will pay off, helping to answer basic questions that will lead to better treatments down the road.

So far, the foundation has given $387,300 to Cold Spring Harbor Laboratory for research. They also gave $50,000 to Make-a-Wish in Suffolk, and $25,000 to local scholarships. The foundation supported Memorial Sloan Kettering with an iPad program. Ultimately, Renna believes in the ongoing return from research investments.

“Everybody wants to find and fund the silver bullet,” he said. “Everybody wants to give money to fund a clinical trial. Basic research is where the discoveries are made.”

Renna urged people creating foundations to have a strong board that included business people and that might also have a scientific or medical advisory element. He also suggested funding foundations a year ahead of time. That helped his foundation in 2020, when finding donors became more challenging during the pandemic.

Being at Cold Spring Harbor Laboratory and helping others get through darker days that are all too familiar to him gives Renna comfort. “I know, in some way, every single day, I’m making an impact,” he said. “How measurable it is, I don’t know. There are days when I’m pretty proud.”

As far as he feels they have come, Renna said it’s not the time to look back, but to press ahead.

T.J. Arcati

A former summer intern in Bruce Stillman’s lab when he attended Notre Dame, T.J. Arcati was married and had two children when he succumbed to sarcoma.

“We know what we went through,” said his father, Tom Arcati, an oral and maxillofacial surgeon in Huntington. “He left a son and a daughter without a dad.”

Tom and his wife Nancy, who raised T.J. in Lloyd Harbor and live in Huntington, were with their son for his treatments and therapies.

Tom and Nancy Arcati are determined to extend people’s lives by more than a year or two and are actively engaged with other families who are coping in the midst of the cancer storm. “I’m talking to people now that unfortunately are going through what we did seven years ago,” Tom Arcati said.

While the Arcatis support other families, their empathy “brings you back to a place you never really leave,” Nancy Arcati said. These interactions “keeps T.J.’s life on people’s minds and in their hearts.”

Tom Arcati tries to be a source of solace to people who are trying to gather information.

In the aftermath of TJ’s death at the age of 34, Arcati reached out to Stillman to see if the lab could work towards better treatments.

One Saturday, Arcati and his son Matthew went to Stillman’s house, where they sat in his living room, with Stillman drinking tea and Arcati having coffee.“What do you think?” Arcati recalled asking. “Are you going to do sarcoma research?” Stillman looked back at his guest and mentioned that he was thinking about it. Stillman called Arcati a few days later.

“When he called me, he said, ‘We’re a cancer institute. We should be doing sarcomas.’ That’s how I remember this whole thing going down. It was pretty heart warming.”

The first step for CSHL was to host a Banbury conference. The site of international meetings on a range of scientific topics since 1978, the Banbury center brings together experts in various fields. The meetings provide a forum for scientific advances and result in various publications. By holding a Banbury Center meeting, CSHL helped advance research into sarcomas.

The Arcatis have remained active in the Friends of T.J. Foundation, which TJ and several college friends founded in 2009 after T.J. was diagnosed with sarcoma. They have stayed in close contact with CSHL Professor Chris Vakoc and his PhD student Martyna Sroka, who regularly keeps him informed of her progress. Sroka has spoken at some of the outings for the Friends of TJ Foundation. This year, Stillman will speak at the September 13th fundraiser at the Huntington Country Club.

“It’s really imperative that people who are supporting us know what their dollars are being spent on,” Arcati said.

The Friends of TJ Foundation has raised about $50,000 each year, bringing their total fundraising to about $400,000.

Arcati hopes something positive can come out of the losses the families who are funding Vakoc’s research suffered.

“If we can save one kid’s life somewhere by doing what we’re doing, then this whole process is worth it,” Arcati said.

Michelle Paternoster

Michelle Paternoster of Lindenhurst developed sarcoma in her sinuses. Her husband Paul Paternoster helped her through 38 surgeries, over 90 radiation treatments and several rounds of chemotherapy.

Michelle and Paul Paternoster

The couple tried immune therapy in the Bahamas in the fall of 2008 and went to New York in 2011 for treatment.

“We drove [to the city] for 90 days” excluding weekends, Paternoster recalled. The treatments seemed to have a positive effect during the trial, but shortly afterward, the cancer continued growing.

After Michelle died in 2013 at the age of 34, Paternoster was determined to help others, initially asking supporters to contribute to the fundraising effort from the Arcatis.

Donations to the Friends of T.J. Foundation reached $30,000, which helped underwrite the Banbury conference at Cold Spring Harbor Laboratory. Michelle and T.J. had seen each other in the radiation suite in the halls of Memorial Sloan Kettering.

Paternoster then started the Michelle Paternoster Foundation for Sarcoma Research. The President of Selectrode Industries Inc., which manufactures welding products and has two factories in Pittsburgh, Paternoster wanted to help people at a clinical level.

Through Michelle’s Clubhouse, he partnered with the Children’s Hospital of Pittsburgh, paying for hotels of pediatric cancer patients when the Ronald McDonald house is full. The clubhouse also provides gift cards to help pay for gas, tolls and copays on prescriptions.

“Knowing how difficult it is to go through this, I can’t imagine what it’s like to not have that capability” to pay for basic needs during treatment, Paternoster said. “That is why it is so important for our board to do something at the clinical level to support families in this battle.”

Paternoster said the relatively small but growing size of the group dedicated to helping each other makes each person’s contribution that much more important.

“Normally, when you’re doing any kind of charity work, you feel like you’re a tiny part of this project, especially when it comes to [diseases like] breast cancer and things that impact millions of people,” Paternoster said. When he attended the Banbury conference that launched the research effort at Cold Spring Harbor Laboratory, he said “you felt you could make a difference. You’re sitting in a room with 25, 30 people max. That was the entire effort to eradicate this disease.”

Paternoster, who lives in Cold Spring Harbor, called the collaboration that came out of the meeting “astounding.”

The Michelle Paternoster Foundation has raised $500,000, with about $350,000 of that supporting the work at Cold Spring Harbor Laboratory.

Ultimately, like the other families who raise funds, stay informed and offer help to strangers battling an all-too-familiar disease, Paternoster feels that the opportunity to make a meaningful contribution inspires him.

“That’s our dream,” he said, “to find a cure, so other people don’t have to feel what we felt.”

To read Part 1 of the article click here.

by -
0 1751
Martyna Sroka. Photo by Sofya Polyanskaya

By Daniel Dunaief

Part 1:

A group of people may prove to be the guardian angels for the children of couples who haven’t even met yet.

After suffering unimaginable losses to a form of cancer that can claim the lives of children, several families, their foundations, and passionate scientists have teamed up to find weaknesses and vulnerabilities in cancers including rhabdomyosarcoma and Ewing sarcoma.

Rhabdomyosarcoma affects about 400 to 500 people each year in the United States, with more than half of those patients receiving the diagnosis before their 10th birthday. Patients who receive diagnoses for these cancers typically receive medicines designed to combat other diseases.

 

Christopher Vakoc. Photo from CSHL

A group of passionate people banded together using a different approach to funding and research to develop tools for a different outcome. Six years after the Christina Renna Foundation and others funded a Banbury meeting at Cold Spring Harbor Laboratory, the grass roots funders and dedicated scientists are finding reasons for optimism.

“I wish I could run up to the top of a hill and scream it out: ‘I’m more hopeful than I’ve ever been,’” said Phil Renna, director of operations, communications department at CSHL and the co-founder of the Christina Renna Foundation. “I’m really excited” about the progress the foundation and the aligned group supporting the Sarcoma Initiative at the lab has made.

Renna and his wife Rene started the foundation after their daughter Christina died at the age of 16 in 2007 from rhabdomyosarcoma. Renna’s optimism stems from work Cold Spring Harbor Laboratory’s Christopher Vakoc, a professor and Cancer Center co-director and his research team, including PhD candidate Martyna Sroka have performed.

The cause for optimism comes from the approach Vakoc has taken to cancers, including leukemia.

Vakoc has developed a way to screen the effects of genetic changes on the course of cancer.

“Usually, when you hear about a CRISPR screen, you think of taking out a function and the cell either dies or doesn’t care,” Sroka said, referring to the tool of genetic editing. Sroka is not asking whether the cell dies, but whether the genetic change nudges the cellular processes in a different direction.

“We are asking whether a loss of a gene changes the biology of a cell to undergo a fate change; in our case, whether cancer cells stop growing and differentiate down the muscle lineage,” she explained.

In the case of sarcoma, researchers believe immature muscle cells continue to grow and divide, turning into cancer, rather than differentiating to a final stage in which they function as normal cells.

Through genetic changes, however, Sroka and Vakoc’s lab are hoping to restore the cell to its non cancerous state.

Cold Spring Harbor Laboratory has had success with other diseases and other types of cancer, which is where the optimism comes from, explained Paul Paternoster, President of Selectrode Industries, Inc. and the founder of the Michelle Paternoster Foundation for Cancer Research.

As a part of her doctoral research which she’s been conducting for four years, Sroka is also working with Switzerland-based pharmaceutical company Novartis AG to test the effect of using approved and experimental drugs that can coax cells back into their muscular, non-cancerous condition.

The work Sroka and Vakoc have been doing and the approach they are taking could have applications in other cancers.

“The technology that we’ve developed to look at myodifferentiation in rhabdomyosarcoma can be used to study other cancers (in fact, we are currently applying it to ask similar questions in other cancer contexts),” said Sroka. “In addition, our findings in RMS might also shed light on normal muscle development, regeneration and the biology of other diseases that impact myodifferentiation, e.g. muscular dystrophy.”

Martyna Sroka’s journey

Described by Vakoc as a key part of the sarcoma research effort in his lab, Martyna Sroka, who was born and raised in Gdańsk, Poland, came to Long Island after a series of eye-opening medical experiences.

In Poland, when she was around 16, she shadowed a pediatric oncology doctor who was visiting patients. After she heard the patient’s history, she and the doctor left the room and convened in the hallway.

Martyna Sroka. Photo by Sofya Polyanskaya

“He turned to me and said, ‘Yeah, this child has about a month or two tops.’ We moved on to the next case. I couldn’t wrap my head around it. That’s as far as we could go. There’s nothing we could do to help the child and the family,” said Sroka.

Even after she started medical school, she struggled with the limited ammunition modern medicine provided in the fight against childhood cancer.

She quit in her first year, disappointed that “for a lot of patients diagnosed with certain rare types of tumors, the diagnosis is as far as the work goes. I found that so frustrating. I decided maybe my efforts will be better placed doing the science that goes into the development of novel therapies.”

Sroka applied to several PhD programs in the United Kingdom and only one in the United States, at Cold Spring Harbor Laboratory, where she hoped to team up with Vakoc.

Sroka appreciated Vakoc’s approach to the research and his interest in hearing about her interests.

“I knew that we could carve out an exciting scientific research project that tries to tackle important questions in the field of pediatric oncology, [the] results of which could potentially benefit patients in the future,” she explained in an email.

The two of them looked at where they could make a difference and focused on rhabdomyosarcoma.

Sroka has “set up a platform by which advances” in rhabdomyosarcoma medicines will be possible, Vakoc said. “From the moment she joined the sarcoma project, she rose to the challenge” of conducting and helping to lead this research.

While Sroka is “happy” with what she has achieved so far, she finds it difficult at times to think about how the standard of care for patients hasn’t changed much in the last few decades.

“Working closely with foundations and having met a number of rhabdomyosarcoma patients, I do feel an intense sense of urgency,” she wrote.

Read Part 2 here.

 

by -
0 920
Maurizio Del Poeta in his laboratory at Stony Brook University. Photo by Antonella Rella

By Daniel Dunaief

Researchers at Stony Brook University, the University of Arizona and Wake Forest University School of Medicine in North Carolina may have found an enzyme that drives the worst COVID-19 symptoms. Secreted phospholipase A2 group IIA, or sPLA2-IIA may lead to severe symptoms and death, making this enzyme a potential therapeutic target.

P116, Maurizio DelPoeta, Microbiology

In an examination of plasma samples from 127 patients hospitalized at Stony Brook University Medical Center between January and July 2020 and a mix of 154 patient samples from Stony Brook and Banner University Medical Center in Tucson between January and November 2020, scientists including Distinguished Professor Maurizio Del Poeta of the Renaissance School of Medicine at Stony Brook University found that 63 percent of people with concentrations of the enzyme that were over 10 nanograms/ milliliter generally died. Most healthy people have circulating levels of the enzyme around 0.5 nanograms/ milliliter.

“It is possible that sPLA2 levels represent a tipping point and when it reaches a certain level, it is a point of no return,” said Del Poeta.

The collaborators involved in the study, which was published this week in the Journal of Clinical Investigation, were encouraged by the finding.

“This is exciting as it is leading to really novel connections for COVID-19,” Yusuf Hannun, Director of the Cancer Center at Stony Brook and a contributor to the research who participated in the discussion and data analysis, explained in an email. “It may lead to both diagnostics (for risk prediction) and therapeutics.”

Looking closely at the levels of sPLA2-IIA together with blood urea nitrogen, or BUN, which is a measure of the performance of the kidney, the researchers in this study found that the combination of the two measures predicted mortality with 78 percent accuracy.

“That is an opportunity to stratify patients to those where an inhibitor” to sPLA2-IIA could help patients, said Floyd Chilton, director of the University of Arizona Precision Nutrition and Wellness Initiative and senior author on the paper, said.

While they found a difference in the amount of the enzyme between healthier and sicker patients, the scientists recognize that this could reflect a correlation rather than a causation. The progression of the disease and the threat to people’s lives may come from other contributing factors that also intensify the severity of the illness.

“These studies do not establish causality at the moment, but the strength of the correlation and the known functions of this enzyme raise the possibility of participating in the pathology of the disease,” Del Poeta explained.

Floyd Chilton. Photo from University of Arizona

Indeed, Chilton has studied sPLA2-IIA for over three decades and has described some patterns in other diseases, including sepsis.

The enzyme performs an important role in fighting off bacterial infection by destroying microbial cell membranes. When the concentration of sPLA2-IIA rises high enough, however, it can threaten the health of the patient, as it can attack and destroy cells in organs including the kidney.

The enzyme “plays a critical role in host defense,” said Chilton. “These same systems can really turn on the host.”

In order to determine a causative link between sPLA2-IIA and the progression of the disease, Chilton, Del Poeta and others will need to increase their sample size.

“We’ve been very fortunate at getting individuals at some of the top global organizations… who have connected me with medical centers” that have a larger patient population, Chilton said. These executives may be able to expedite the process of expanding this study.

In the 1990’s, scientists studied an inhibitor that had the ability to act on the enzyme. 

That effort had mixed results in phase 2 clinical trials.

“In 2005, the first phase of the phase 2 clinical trials were highly encouraging,” Chilton said. “It really inhibited mortality at 18 hours” by reducing severe sepsis. The second part of those tests, which used a slightly different protocol, failed.

While he’s not a clinical trials expert, Chilton is hopeful that researchers might find success with this same drug to treat COVID-19.

Only clinical trials would reveal whether inhibitors would work with COVID-19, scientists said.

As with many drugs, inhibitors of sPLA2-IIA have side effects.

By blocking the activity of these enzymes, “we do also decrease the production of arachidonic acid, which is a precursor of prostaglandins,” said Del Poeta. “In condition of hyperinflammation, this is a good thing, but prostaglandins are also important in a variety of cellular functions” including blood clots and starting labor.

Chilton pointed out that sPLA2-IIA is similar to the active enzyme in rattlesnake venom. It can bind to receptors at neuromuscular junctions and disable the function of these muscles, he explained.

In nature, some animals have co-evolved with snakes and are no longer susceptible to these toxins. Researchers don’t yet understand those processes.

While copying such evolutionary solutions is intriguing, Chilton said he and his collaborators are “much more interested in the inhibitors” that were taken through clinical trials in 2005 because that might present a quicker solution.

The research collaboration started with Chilton, who partnered with Arizona Assistant Research Professor Justin Snider. The first author on the paper, Snider earned his PhD at Stony Brook, where he knew Del Poeta well.

Snider “knew what a great researcher [Del Poeta] was. I also knew [Hannun] in a former life. We were both working on similar biochemistry 20 to 25 years ago,” Chilton said.

Chilton called the efforts of his Stony Brook collaborators, including Research Assistant Karen You, Research Associate Professor Chiara Luberto and Associate Professor Richard Kew,  “heroic” and explained that he and his colleagues recognize the urgency of this work.

“I’ve been continuously funded by the [National Institute of Health] for 35 years, and I’m very grateful for that,” Chilton said. “There is nothing in my life that has felt this important,” which is why he often works 18 hour days, including on weekends.

After studying the effects of variants on the population, Chilton recognized that building a firewall against COVID-19 through vaccinations may not be enough, especially with the combination of lack of access to the vaccine for some and an unwillingness to take the vaccine from others.

“We may have to go to the other side of the equation,” HE said. “We’ve got to move to specific therapeutics that are agnostic to the variant.”

by -
0 2786
BNL LECTURE: ZHANGBU XU

By Daniel Dunaief

Gregory Breit and John Wheeler were right in the 1930s and Werner Heisenberg and Hans Heinrich Euler in 1936 and John Toll in the 1950s were also right.

Breit, who was born in Russia and came to the United States in 1915, and Wheeler, who was the first American involved in the theoretical development of the atomic bomb, wrote a paper that offered theoretical ideas about how to produce mass from energy.

Breit and Wheeler suggested that colliding light particles could create pairs of electrons and their antimatter opposites, known as positrons. This idea was an extension of one of Albert Einstein’s most famous equations, E=mc2, converting pure energy into matter in its simplest form.

Zhangbu Xu in front of the time-of-flight detector, which is important for identifying the electrons and positrons the STAR Collaboration measured. Photo from BNL

Working at the Relativistic Heavy Ion Collider (RHIC) at Brookhaven National Laboratory, a team of scientists in the STAR Collaboration has provided experimental proof that the ideas of some of these earlier physicists were correct.

“To create the conditions which the theory predicted, even that process is quite exhausting, but actually quite exciting,” said Zhangbu Xu, a senior scientist at BNL in the physics department.

The researchers published their results recently in Physics Review Letters, which provides a connection to Breit and Wheeler, who published their original work in a predecessor periodical called Physics Review.

While Breit and Wheeler wrote that the probability of two gamma rays colliding was “hopeless,” they suggested that accelerated heavy ions could be an alternative, which is exactly what the researchers at RHIC did.

The STAR team, for Solenoidal Tracker at RHIC, also proved another theory proposed decades ago by physicists Heisenberg, who also described the Heisenberg Uncertainty Principle, and Hans Heinrich Euler in 1936 and John Toll, who would later become the second president at Stony Brook University, in the 1950s.

These physicists predicted that a powerful magnetic field could polarize a vacuum of empty space. This polarized vacuum should deflect the paths of photons depending on photon polarization.

Researchers had never seen this polarization-dependent deflection, called birefringence, in a vacuum on Earth until this set of experiments.

Creating mass from energy

Xu and others started with a gold ion. Without its electrons, the 79 protons in the gold ion have a positive charge, which, when projected at high speeds, triggers a magnetic field that spirals around the particle as it travels.

Once the ion reaches a high enough speed, the strength of the magnetic field equals the strength of the perpendicular electric field. This creates a photon that hovers around the ion.

The speeds necessary for this experiment is even closer to the speed of light, at 99.995%, than ivory soap is to being pure, at 99.44%.

When the ions move past each other without colliding, the photon fields interact. The researchers studied the angular distribution patterns of each electron and its partner positron.

“We also measured all the energy, mass distribution, and quantum numbers of the system,” Daniel Brandenburg, a Goldhaber Fellow at BNL who analyzed the STAR data, said in a statement.

Even in 1934, Xu said, the researchers realized the cross section for the photons to interact was so small that it was almost impossible to create conditions necessary for such an experiment.

“Only in the last 10 years, with the new angular distribution of e-plus [positrons] and e-minus [electrons] can we say, ‘Hey, this is from the photon/ photon creation,’” Xu said.

Bending light in a vacuum

Heisenberg and Euler in 1936 and Toll in the 1950’s theorized that a powerful magnetic field could polarize a vacuum, which should deflect the paths of photons. Toll calculated in theory how the light scatters off strong magnetic fields and how that connects to the creation of the electron and positron pair, Xu explained. “That is exactly what we did almost 70 years later,” he said.

This is the first experiment on Earth that demonstrates experimentally that polarization affects the interactions of light with the magnetic field in a vacuum.

Xu explained that one of the reasons this principle hasn’t been observed often is that the effect is small without a “huge magnetic field. That’s why it was predicted many decades ago, but we didn’t observe it.”

Scientists who were a part of this work appreciated the connection to theories their famous and successful predecessors had proposed decades earlier.

“Both of these findings build on predictions made by some of the great physicists in the early 20th century,” Frank Geurts, a professor at Rice University, said in a statement. 

The work on bending light through a vacuum is a relatively new part of the research effort.

Three years ago, the scientists realized they could study this, which was a surprising moment, Xu said.

“Many of our collaborators (myself included) did not know what vacuum birefringence was a few years ago,” he said. “This is why scientific discovery is exciting. You don’t know what nature has prepared for you. Sometimes you stumble on something exciting. Sometimes, there is a null set (empty hand) in your endeavor.

Xu lives in East Setauket. His son Kevin is earning his bachelor’s degree at the University of Pennsylvania, where he is studying science and engineering. His daughter Isabel is a junior at Ward Melville High School.

As for the recent work, Xu, who earned his PhD and completed two years of postdoctoral research at Yale before coming to BNL, said he is pleased with the results.

“I’ve been working on this project for 20 years,” he said. “I have witnessed and participated in quite a few exciting discoveries RHIC has produced. These are very high on my list.”

by -
0 1719
From left, postdoctoral researcher Yunjun Zhao and Brookhaven Lab biochemist Chang-Jun Liu in a greenhouse with poplar trees. Photo from BNL

By Daniel Dunaief

Plants not only make our food, produce the oxygen we breathe, and provide key ingredients in medicines, but they could also contribute chemicals that might otherwise require fossil fuels to produce.

Scientists have known since 1955 that poplar trees produce small amounts of a product called p-hydroxybenzoic acid that they attach to the lignin in their cell walls. What they didn’t know, however, was how they were attached.

After years of cloning genes and, more recently, using the gene editing tool CRISPR, Chang-Jun Liu, a plant biochemist at Brookhaven National Laboratory, and collaborators in Japan discovered the gene that codes for an enzyme that catalyzes the attachment of pBA to the lignin.

Up to now, companies have produced pBA by using fossil fuels as raw materials and for the energy required to generate enough heat and pressure for the catalytic reactions.

This discovery, which Liu published in the journal Nature Plants, could provide a more eco-friendly way to produce a chemical involved in the manufacture of toothpaste, shampoos, commercial moisturizers, shaving gels, and spray tanning solutions, among other products.

The global market value of p-hydroxybenzoic acid was $59 million in 2020 and is expected to climb to $80 million in the next five years.

“We wanted to identify the enzyme that is responsible for attaching pBA into lignin and reconstitute this pathway and promote its storage in the cell wall,” Liu said. Ideally, he’d like to combine the pathways that produce the donor molecule containing pBA with their enzyme to promote pBA storage in cell walls.

Once Liu found the gene responsible for that enzyme, he did what scientists typically do to check on the importance of a genetic sequence: first, he knocked it out and second, he overexpressed it.

By knocking out the genetic sequence, he found that poplar trees stopped producing pBA. Overexpressing the gene, on the other hand, not only increased the amount of this chemical by about 48 percent, but also raised the strength of the lignin and, consequently, the durability of the cell wall.

Aside from the benefit of increasing the natural production of the chemical, changing the amount of pBA could have implications for the environment and industry. Less durable lignin, which has a lower amount of pBA, could be useful in producing pulp, paper and biofuel, making it easier to access the biomass of the wood.

More durable lignin could be useful in the timber industry, while also enabling the plant to remove more carbon, mostly in the form of carbon dioxide, from the air.

“If we can engineer the plant to produce more of this carbon-dense compound, … particularly in the root, we can fix more carbon into the underground fraction, which will absorb more carbon from the air to promote carbon sequestration,” Liu said.

A long process

The work that led to identifying the gene that codes for the enzyme that attaches pBA to lignin took about 15 years.

Liu knew this enzyme worked to attach pBA, among other chemicals, in a test tube, but the journey to prove its importance in the poplar trees took considerable work.

Liu cloned 20 genes that are expressed in woody tissues and encoded enzymes called acyltransferases. While expressing these enzymes, he mixed them with an isotope-labeled carbon, which allowed him to check to see whether the enzyme contributed to the process of attaching pBA to lignin.

He tried using RNA interference to knock down the targeted gene, but that didn’t work.

The breakthrough that established the importance of this gene came when Liu used CRISPR. 

Next steps

Scientists aren’t sure of the specific steps or even why plants produce pBA in the first place.

Plants produce pBA through the shikimate pathway, but the exact routes leading to pBA formation are still undiscovered. 

As for why plants produce pBA, one hypothesis is that the plant uses a higher amount as a defense mechanism, making its lignin harder to remove for an insect. It could also provide resistance to mechanical stress caused by wind or snow.

“We do not have solid evidence to prove that,” he said, but “we need to explore that further.”

Liu also hopes to take a synthetic biology approach to build a more effective pathway by using the enzyme to make the plant a partner in producing pBA and in capturing and storing organic carbon.

The biochemist hopes to find a commercial partner who might be interested in exploring the development of a process that occurs naturally in poplar trees.

The environmental impact of increasing pBA in plants on the ecology of the areas in which these poplar trees might grow is unclear.

“We do not know at this moment whether this will benefit or be harmful to the soil microbial community,” he said. “In some cases, it can help the plant absorb more nutrients. It potentially can also kill other microbial life.”

For the plant, it’s unclear what the effect of higher pBA might be. The enzyme Liu identified moves pBA from inside the cell to the cell where, which would likely mitigate any toxicity because that is dead material. 

“We expect the increase of cell wall-bound pBA should promote the trees’ ability in withstanding environmental changes,” he explained.

Altering the cell’s metabolic processes by rebuilding a new pathway that produces high amounts of pBA could negatively affect a tree’s normal growth. Liu would need to conduct more experiments to explore this possible effect.

A resident of Rocky Point, Liu lives with his wife Yang Chen, who is a special education teacher assistant at Rocky Point Middle School. Their son Allen is in his third year at Purdue University, while Bryant is in his second year at the University of Southern California. The family enjoys skiing and hiking trips.

The work to confirm the link between the gene and the production of pBA involved numerous post doctoral researchers.

Liu appreciates the effort of his research team over the years. “I’m very happy that we were finally able to resolve this issue,” he said.

by -
0 1158
H. Reşit Akçakaya during a recent bird watching expedition. Photo by T. Lybvig

By Daniel Dunaief

In the world of conservation, scientists and policy makers have relied on the International Union for Conservation of Nature Red List of Threatened Species to understand just how likely species are to go extinct, often as a result of human actions.

When a species moves from one threat level to another, conservationists typically spring into action, taking steps to protect individuals within a species and the habitat in which that species lives.

A team of over 200 scientists in 171 institutions tested a new measure, called the Green Status, that is designed to measure how effective those conservation efforts have been.

“There are always stories about conservation successes,” said H. Reşit Akçakaya, one of the leaders of the effort who helped develop the methodology for this new metric. The scientists wanted to “create a standard, objective way of recognizing the success and effectiveness of conservation measures. That is very important. We need optimism. People don’t act unless there is hope.”

The Green Status monitors a species recovery, measuring the impact of past and future conservation efforts. Researchers including Akçakaya, who is a Professor in the Department of Ecology and Evolution at Stony Brook University, came up with a formula to determine Green Status. 

The formula includes elements conservations consider important: it should be safe from extinction, it should have a large enough population to have all its natural interactions with the other parts of the ecosystem, and it should be represented in every ecosystem in which it naturally exists and has existed.

The scientists considered the trade-offs between practicality in aiming for a system that is feasible to apply to many species and comprehensiveness, which incorporates relevant aspects of, and factors involved in, species recovery, Akçakaya explained in an email.

The International Union for Conservation of Nature Green Status of Species will join the IUCN Red List to provide a more complete update on a species’ conservation condition, which includes their extinction risk and recovery process.

In a new paper, published in Conservation Biology, scientists from around the world contributed to creating preliminary Green Status for 181 species.

It took seven years from the time the scientists came up with the method, developed it further to make it applicable to all species, published papers, organized workshops and other consultations to get feedback and tested the method.

Akçakaya, who has been involved with the Red List since 1999, said the new system provides information about the status of the species that goes beyond the risk of extinction.

“It’s not sufficient to prevent extinction,” Akçakaya said. “We want them to recover as well.”

One of the challenges in developing this method was in deriving definitions that apply across all species and that are not specific to the conditions and threats any one species faces.

Extinction is difficult to measure but easy to conceptualize, he explained. Recovery, on the other hand, is “not as clear cut.”

The first goal of this enterprise was to come up with ways of standardizing how to measure the recovery of a species that would reflect whether conservation efforts were working.

A species on the Red List might have been critically endangered over a decade earlier. After considerable conservation effort, that species may still be critically endangered, according to the same Red List.

That, however, does not indicate anything specific about whether the conservation efforts are working.

The Red List “doesn’t tell us how much more we need to work to get to a level that we can call recovered,” Akçakaya explained.

The Green Status is not currently a part of conservation policy decisions, particularly because it has only been applied to 181 species. The IUCN, however, which is the world’s largest network of conservationists and conservation scientists, has approved it.

Getting from 181 to tens of thousands will take several years, although Akçakaya said he “has a good start” and he has interest from different people who are involved in conservation.

“We are on our way” towards creating a metric that affects conservation policy, he said. “It will take several years to be used” to affect conservation policies for threatened species.

When the Green Status is more broadly available for a wider collection of species, Akçakaya believes it will provide a way for government officials to make informed decisions.

The IUCN, however, does not tell local and national officials what to do with the information provided with the Red List or with the Green Status.

In developing the Green Status, Akçakaya worked with numerous scientists and conservationists. For this methodology, the researchers received hundreds of comments from people who  shared insights online. They also announced the work within the IUCN network, through which they received feedback.

Part of the larger advances in the context of the Green Status came from looking not only at the resilience of the species, but also at what the species is doing in the ecosystem. “Is it fulfilling its ecological role and its function in the ecosystem?” Akçakaya asked.

The Stony Brook scientist is pleased with the Green Status work. The intelligence of the group is larger than the intelligence of any one person, he said.

The group “had the same goal,” he added. “It was a really satisfying experience in terms of how we came up with a system.”

The Green Status can help balance the conservation news. While conserving biodiversity is urgent, one of the things this measure can achieve is to formalize the successes.

by -
0 1457
Attendees at a conference at CSHL, an in-person tradition started in 1933. These conferences were suspended from 1943 to 1945 during WWII and were virtual during the pandemic in 2020 and for most of 2021. Photo by Miriam Chuai/CSHL

By Daniel Dunaief

For scientists, meetings and conferences aren’t just a chance to catch up on the latest research, gossip and see old friends: they can also provide an intellectual spark that enhances their careers and leads to new collaborations.

Amid the pandemic, almost all of those in-person conferences stopped, including the annual courses and meetings that Cold Spring Harbor Laboratory hosts. The internationally renowned lab has run meetings since 1933, with a few years off between 1943 and 1945 during World War II.

CSHL’s David Stewart. Photo by Gina Motisi/CSHL

While scientists made progress on everything from basic to translational research, including in laboratories that pivoted towards work on the SARS-CoV-2 virus, which causes COVID-19, they missed out on the kinds of opportunities that come from in-person interactions.

Assuming COVID infection rates are low enough this fall, CSHL is hoping to restart in-person conferences and courses, with the first conference that will address fifty years of the enzyme reverse transcriptase scheduled for Oct. 20th through the 23rd. That event was originally scheduled for October of 2020.

One of the planned guest speakers for that conference, David Baltimore, who discovered the enzyme that enables RNA to transfer information to DNA and is involved in retroviruses like HIV, won the Nobel Prize.

“I am hoping that there will be significant participation by many eminent scientists, so that is in itself somewhat [of] a ceremonial start,” wrote David Stewart, Executive Director of meetings and courses at Cold Spring Harbor Laboratory.

To attend any of the seven in-person meetings on the calendar before the end of the year, participants need to have vaccinations from either Pfizer, Moderna, Johnson & Johnson or AstraZeneca.

Attendees will have to complete an online form and bring a vaccination card or certificate. Scientists who don’t provide that information “will not be admitted and will not get a key to their room or be able to attend the event,” Stewart said.

CSHL also plans to maintain the thorough and deep cleaning procedures the lab developed. 

Stewart hopes that 75 to 80 percent or more of the talks presented will be live, with a virtual audience that could be larger than the in-person attendance.

“It is important to have a critical mass of presenters and audience in-person, but there’s no real limit on how large the virtual audience could be,” he explained.

Typically, the courses attract participants from over 50 countries. Even this year, especially with travel restrictions for some countries still in place, Stewart expects that the majority of participants will travel from locations within the United States.

The Executive Director explained that CSHL was planning to introduce a carbon offset program for all travel to conferences and courses that the facility reimburses starting in 2020. After evaluating several options, they plan to purchase carbon offsets from Cool Effect and will encourage participants paying their own way to do the same or through a similar program.

The courses, meanwhile, will begin on October 4th, with macromolecular crystallography and programming for biology. CSHL hopes to run six of these courses before the end of the year, including a scientific writing retreat.

“We are looking to 100 percent enrollment for our courses, so likely this year that will largely be domestic,” Stewart explained.

The courses, which normally have 16 participants, may have 12 students, as the lab tries to run these training opportunities safely without masks or social distancing.

From March of 2020 through the end of last year, the lab had planned 25 meetings and 25 courses. As the pandemic spread, the lab pivoted to virtual meetings. “I felt like a car salesman trying to sell virtual conferences,” Stewart recalled. For the most part, the lab was able to keep to its original schedule of conferences, albeit through a virtual format.

In addition to the scheduled meetings, CSHL decided to add meetings to discuss the latest scientific information related to COVID research. 

Stewart approached Hung Fan, a retired virologist at the University of California at Irvine, to help put together these COVID exchanges. Those meetings occurred in June, July, August, October, and January. The sixth one recently concluded.

The meetings addressed “everything around the science of the virus,” Stewart said, which included the biology, the origin, the genomics, the immune response, vaccines, therapeutics and diagnostics, among other scientific issues.

“There was a lot of excellent work being done around SARS-CoV-2,” Stewart said. “We were trying to identify that early on. It was helpful to have people who knew the field well.”

Fan said he combed through preprints like the CSHL-based bioRxiv and related medRxiv every day for important updates on the disease.

Fan described the scientific focus and effort of the research community as being akin to the Manhattan Project which built the atomic bomb during World War II, where “everybody said, ‘We have a common enemy and we want to apply all our capabilities to combating that.”

While Fan is pleased with the productive and valuable exchanges that occurred amid the virtual conferences, he recognized the benefit of sharing a room and a drink with scientific colleagues.

“A lot of the productive interactions at meetings take place in a social setting, at the bar, over dinner” and in other unstructured gatherings, he said. “People are relaxed and can share their scientific thoughts.”

After presentations, Fan described how researchers discuss the work presented and compare that to their own efforts. It’s easier to talk with people in person “as opposed to making a formalized approach through letters and emails.”

by -
0 1723
A group of gelada monkeys in Ethiopia. Photo from Jacob Feder

By Daniel Dunaief

Timing can mean the difference between life and death for young geladas (an Old World monkey species). Geladas whose fathers remain leaders of a social group for as much as a year or more have a better chance of survival than those whose fathers are displaced by new males under a year after they’re born. 

New males who enter a social group can, and often do, kill the young of other males, giving the new male leaders a chance to impregnate the female members of their social group who might otherwise be unable to conceive.

Jacob Feder

 

The odds of a new male leader killing a young gelada are about 60 percent at birth, compared to closer to 15 percent at around a year of age, according to researchers at Stony Brook University (SBU).

Additionally, pregnant gelada monkeys often spontaneously abort their unborn fetuses once a new male enters the group, as the mother’s hormones cause a miscarriage that enables them to dedicate their resources to the future progeny of the next dominant male.

At the same time, the survival of females depends on becoming a part of a group that is just the right size.

Jacob Feder, a graduate student at SBU, and Amy Lu, Assistant Professor in the Department of Anthropology in the College of Arts and Sciences at Stony Brook, recently published a paper in Proceedings of the Royal Society B that explores the ideal group size that optimizes the longevity of females and the number of their offspring.

The researchers discovered a Goldilocks effect. By studying the behavioral and group data for over 200 wild geladas over the course of 14 years, they determined that a mid-size group with five to seven females has the greatest benefit for their own fitness and for the survival of their offspring.

“There tends to be a trade off” in the dynamics that affect female geladas in different groups, Feder said. Females in the biggest groups face a higher risk of takeovers and takeover-related infanticide, since males are more likely to try to dominate a part of larger social groups where they have greater reproductive opportunities.

By contrast, individuals in the smaller groups may live on the periphery of a multi-group dynamic. These females are less protected against predators.

In their native Ethiopia, geladas are vulnerable to leopards, hyenas, and jackals, among others.

For the females, the survival of their offspring depends on the ability of males to remain in the group long enough.

“The male turnover is one of the major drivers of their reproductive success,” explained Feder.

Researchers have seen new males enter a group and kill infants born from another father. The infants, for their part, don’t often recognize the need to avoid new males, Lu said.

When males enter big groups, females often have to reset their reproduction.

Groups with about nine to 11 females often split into units of four to seven, Feder said. A new male might become the leader for half of the females, leaving the remaining male with the other half. Alternatively, new males may take over each group.

The pregnant females who are part of a group with a new male will spontaneously abort their offspring about 80 percent of the time, as females “cut their losses,” Feder said

About 38 percent of females live in a mid-sized group that is close to optimum size.

Gelada charm

According to Feder and Wu, geladas are a compelling species to research, Feder and Wu said.

Feder found his visits to the East African nation rewarding, especially when he had the opportunity to watch a small female named Crimson.

An important part of daily life for these primates involves grooming, where primates comb through each other’s hair, remove insects and, in many cases, eat them.

Crimson, who was a younger member of the group when Feder started observing geladas, didn’t have much grooming experience with this activity. Instead of running her hands over the body of her grooming partner, she focused on her mouth. Her partner’s wide eyes reflected surprise at the unusual grooming choice.

One of the favorites for Lu was a monkey who has since passed away named Vampire. A part of the V group, Vampire was taller and bigger than most adult females. She displaced male geladas, some of whom were larger than she, almost as often as they displaced her.

“If you go out in the field enough, you know the individuals pretty well,” Lu said. “They all have their own personalities. Some of them walk in a different way and react to situations differently.”

A resident of Centereach, Feder grew up in northern Connecticut, attending Wesleyan University as an undergraduate, where he majored in music and biology. A bass guitar player, Feder said he “dabbles in anything with strings.”

In fourth grade, Feder read a biography of Dian Fossey, which sparked his interest in biology.

While he has yet to combine his musical and science interests with geladas, Feder said these monkeys have a large vocabulary that is almost as big as chimpanzees.

Lu, meanwhile, started studying geladas as a postdoctoral researcher. They’re a great study species that allow scientists to ask compelling questions about reproductive strategies. “At any point, you can follow 20 social groups,” Lu said.

Lu, whose two children are four years old and 16 months old, said she has observed the similarities between human and non-human primate young.

“Babies throw tantrums, whether it is my child or a gelada infant protesting being put on the ground,” she described in an email. Gelada infants use a sad “cooing” sound. Sometimes, the sad cooing sound is real and sometimes “they just get what they want.”

by -
0 1626
Rebecca Smith at the Sólheimajökull glacier in Iceland, where the scientist did field work during the 2015 Astrobiology Summer School. Photo from Rebecca Smith

By Daniel Dunaief

Rocks may not speak, move or eat, but they can and do tell stories.

Recognizing the value and importance of the ancient narrative rocks on Earth and on other planets provide, NASA sent vehicles to Mars, including the rover Perseverance, which landed on February 18 of this year.

Perseverance brought seven instruments, most of them identified by the acronym-loving teams at NASA, that carry out various investigations, such as searching for clues about a water-rich environment that may have sustained life about 3.5 billion years ago.

Several instrument teams developed and monitor these pieces of equipment, including Joel Hurowitz, Associate Professor in the Department of Geosciences at Stony Brook University and Deputy Principal Investigator on the Planetary Instrument for X-ray Lithochemistry, or PiXL.

In addition to the instrument leads, NASA chose participating scientists who can contribute to several teams, providing scientific support for a host of questions that might arise as the rover explores the terrain of the Red Planet 128 million miles from Earth.

Rebecca Smith, a post-doctoral researcher at Stony Brook in Geosciences Professor Scott McLennan’s lab, is one such participating scientist.

“I get to move around between all these different groups, which is fun,” said Smith, whose appointment will last for three years. While the Mars2020 program takes up about 20 percent of Smith’s time, the remainder is focused on the Mars Science Laboratory mission. Smith is likely to spend almost all of her time on Mars2020 starting this September.

Smith has helped make the science plans for the rover. The scientist and other researchers help select targets for the instruments that will help answer specific science questions. For this work, they collaborate with different science teams. Smith plans to get more involved with specific instrument teams soon, including SuperCam, PiXL and Sherloc.

For Smith’s own research, the scientist has a suite of rock samples that include lacustrine carbonates and hydrothermally altered volcanic rocks. The volcanic rocks formed under conditions that might be analogous to those once present in Jezero crater, where the rover landed and is currently maneuvering. The crater is just north of the Martian equator and has a delta that once long ago contained water and, potentially, life.

On Earth, Smith is using versions of the SuperCam, PiXL, and Sherloc to understand how these rocks would look to different instruments and determine what baseline measurements they need to tell the different types of rocks apart using the instruments aboard the rover.

Smith has studied rocks on Earth located in Hawaii, Iceland and the glaciers in the Three Sisters Volcanic Complex in Oregon.

Many planetary geologists use Earth as an analog to understand geologic processes on other planets. It is still uncertain if the climate of early Mars was warn and wet or cold and icy and wet, Smith explained in an email, adding, “It is possible the minerals we see with the rovers and from orbit can help us answer this question.” 

Most of the work the scientist been involved with is trying to understand how Mars-like volcanic rocks chemically weather under different climates.

Through previous research on Mars, scientists discovered that large regions had poorly crystalline materials. The poorly crystalline nature of the materials makes them difficult to identify using rover-based or orbiter-based instruments.

“The fact that they could have formed in the presence of water makes them important to understand,” Smith explained.

Part of the work Smith is doing is to understand if poorly crystalline material formed by water have specific properties that relate to the environment or climate in which they formed.

Smith said the bigger picture question of the work the teams are doing is, “was there life on Mars? If not, why not? We think that Mars, for the first billion years or so, was pretty similar to Earth around the same time and Earth developed life.”

Indeed, Earth had liquid water on its surface, which provided a habitat for microbial life about 3.5 billion years ago.

The ancient rock record on Mars provides a better-preserved history because the Red Planet doesn’t have plate tectonics.

“Based on what we know about Earth, if life ever developed on early Mars, it would likely have been microbial,” Smith wrote.

Other goals of Mars2020 include characterizing the climate and the geology. Both goals focus on looking for evidence of ancient habitable environments and characterizing those to understand a host of details, such as the pH of the water, the temperature and details about how long the water was on the surface.

Part of the reason NASA put out a call for participating scientists is to “bridge instrument data” from different pieces of equipment, Smith explained.

“I love the collaborative nature of working on a team like this,” Smith offered. “Everybody is interested in getting the most important information and doing the best job that we can.”

Smith enjoys the opportunity to study potentially conflicting signals in rocks to determine what they indicate about the past.“Geology is just so complex. It’s a big puzzle. Forces have been acting over a very long period of time and forces change over time. We are trying to tease apart what happened and when.”

While Smith works at Stony Brook, the post-doctoral scientist returned to California during the pandemic to live closer to her family. After finishing the current research program, Smith plans to remain open to various options, including teaching.

Smith appreciates the opportunity to work on the Mars 2020 mission, adding, “I’m really grateful for that during this past year in particular.”

by -
0 1774
Pixabay photo

By Daniel Dunaief

Rain can put a damper on life, as the two children at the beginning of Dr. Seuss’s The Cat in the Hat shared and as the itsy bitsy spider that went up the water spout only to get washed out again discovered.

As it turns out, rain, clouds, wind and foul weather can reduce the trading decisions of people who buy and sell large sums of money in stocks, as they grapple with their own reactions to clouds that they’d like to go away and come again some other day.

Danling Jiang

Danling Jiang, associate dean of research and faculty development in Stony Brook University’s College of Business; Lin Sun, Assistant Professor at George Mason University; and Dylan Norris, Assistant Professor at Troy University recently published a study in which they explored the effect of cloudy or inclement weather in the two weeks before an earnings surprise on investor reactions.

Every three months, public companies provide a detailed disclosure of their profits and losses, giving investors a chance to look over the equivalent of a quarterly report card.

Like helicopter parents who monitor every line, sentence and word in a report card, institutional investors tend to have a stronger reaction, either positively or negatively, if those numbers are considerably different than they expected. An “A” in advanced calculus might be like profits that exceed estimates by 10 percent, while a “C” might be the equivalent of an unexpected loss in a business that had been doing well.

As it turns out, institutional investors are less likely to react as strongly, at least initially, to an earnings surprise if the skies in the two weeks before they review the earnings announcements are cloudy or unpleasant.

“We find strong supporting evidence in our empirical tests which reveal increases in the pre-announcement unpleasant weather of institutional investors results in muted immediate market responses to earnings news and amplified port-earnings-announcement drifts,” Jiang explained in an email.

Over the course of two to three months, the stock price reflects a more typical pattern that aligns with the direction of the earnings surprise.

The researchers published their work in the Journal of Corporate Finance.

These results, which came from an analysis of reactions to earnings surprises from 1990 to 2016, validate and extend previous efforts to understand how weather affects investor decisions.

Earlier studies revealed the effects of weather on individuals’ psychological and physiological states, according to Jiang.

“These effects have also been shown to influence financial decisions and security prices, even through the actions of sophisticated market participants such as market makers and security analysts,” she said.

The three academics started working together when Lin and Jiang were faculty and Norris was a PhD student at Florida State University.

“We were fascinated by the idea present in prior research that weather seems a perfect exogenous shock to investor psychology and physiology,” said Jiang. “This exogenous feature allows us to draw some causality of psychology on market pricing in a new setting with institutional investors and earnings announcements.”

The researchers chose the years 1990 to 2016 because they had the data in their possession.

“We tried to ensure that our sample period was long enough to confirm the weather effect was a persistent force throughout time and not merely a phenomenon of a small segment in time,” said Jiang who added that solving the weather-related muted effect by adding brighter lights to a trading floor could backfire, as excessive bright lights can have negative effects.

“Overillumination can cause fatigue, stress and anxiety,” she explained. “It is also likely that most traders are subject to the weather at some point during the day” through arriving at work, leaving for lunch or glancing out the window. That means the weather still likely influences them even when they may be in a brightly-lit indoor setting.

The researchers used two measures of weather conditions. One integrated wind, cloud and rain, and the other used cloud cover only. Both measures produced similar findings.

Using earlier studies and their own research, it appears accounting for the combined effect of simultaneous weather parameters or focusing on cloud cover better captures any physiological or psychological effects as opposed to using wind or rain alone, said Jiang.

Public companies are unlikely to trigger a more muted response to earnings surprises by recruiting investors from areas with greater cloud cover, as prior research demonstrated that seasonal climate norms don’t appear to affect the behavior of investors once they acclimate, so to speak, to the weather.

In addition to the 14-day window to create the weather measures, the researchers generated a seven-day measure that showed similar results.

Announcement day weather may also affect market reactions to earnings news and “we do not discredit its importance,” Jiang said. Indeed, other research has shown that the weather in New York City at the time of an earnings announcement impacts market reactions.

The explanation for the muted reaction to earnings is based on psychological and physiological reactions of institutional investors to weather, including anxiety and sadness as well as fatigue and decreased activity.

“In addition to causing delayed information processing, weather could cause a reduction in energy amongst some traders,” said Jiang

That means institutional investors may struggle with the same factors that made the boy and Sally from The Cat in the Hat struggle while it was “too wet to go out and too cold to play ball. So we sat in the house, we did nothing at all,” Dr. Seuss wrote.

While institutional investors don’t do nothing at all, they are less active, at least according to the recent research, than they are when the sun shines brightly, reliably and more consistently.

Prev1...171819...65Next Page 18 of 65
TBR News Media is your local news and entertainment website.
We provide you with the latest breaking news and information for your community.
Contact us: [email protected]

Most Viewed

©